Last reviewed · How we verify

Cogna Technology Solutions LLC — Portfolio Competitive Intelligence Brief

Cogna Technology Solutions LLC pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
BBIBP-CorV vaccine BBIBP-CorV vaccine phase 3 Inactivated viral vaccine SARS-CoV-2 viral antigens Immunology / Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Bharat Biotech International Limited · 1 shared drug class
  2. Boryung Pharmaceutical Co., Ltd · 1 shared drug class
  3. Centers for Disease Control and Prevention · 1 shared drug class
  4. Chiang Mai University · 1 shared drug class
  5. China National Biotec Group Company Limited · 1 shared drug class
  6. Clover Biopharmaceuticals AUS Pty · 1 shared drug class
  7. Crucell Holland BV · 1 shared drug class
  8. AJ Vaccines A/S · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Cogna Technology Solutions LLC:

Cite this brief

Drug Landscape (2026). Cogna Technology Solutions LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cogna-technology-solutions-llc. Accessed 2026-05-16.

Related